Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › STEP 1

STEP 1

Semaglutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
obesity
Official title
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2018-06 → 2020-03
Participants
1961
Duration
68 weeks
Registry
NCT03548935

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
semaglutide 2.4 mgobesity681961−16.9 % vs −2.4 %
Δ −14.5 pp
−14.9 % vs −2.4 %
Δ −12.5 pp
−0.5 vs −0.17.0 vs 3.1—44.2 vs 17.424.8 vs 6.69.8 vs 6.4−6.2 vs −1.1verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (5)
  • semaglutide 2.4 mg · ae_dc · Table 3
    | Adverse events leading to discontinuation of drug or placebo | 92 (7.0) | 123 | 7.2 | 20 (3.1) | 23 | 2.8 |
  • semaglutide 2.4 mg · nausea · Table 3
    | Nausea | 577 (44.2) | 1068 | 62.6 | 114 (17.4) | 146 | 17.6 |
  • semaglutide 2.4 mg · vomiting · Table 3
    | Vomiting | 324 (24.8) | 636 | 37.3 | 43 (6.6) | 52 | 6.3 |
  • semaglutide 2.4 mg · sae · Table 3
    | Serious adverse events | 128 (9.8) | 164 | 9.6 | 42 (6.4) | 53 | 6.4 |
  • semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
    | Glycated hemoglobin — percentage points | -0.45 | -0.15 | -0.29 (-0.32 to -0.26) | | |

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: STEP 1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.